Scarica l'app Stockscreener
30.88
0.19%
-0.06
Dopo l'orario di chiusura:
30.58
-0.30
-0.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
Groundbreaking BRIUMVI MS Treatment Data: 4 Critical Studies Reveal Real-World Impact at ACTRIMS - StockTitan
TG Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
TG Therapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 16, 2022 to Discuss Your RightsTGTX - Newsfile
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Entropy Technologies LP - MarketBeat
Bleakley Financial Group LLC Purchases Shares of 8,140 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News
46,655 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Strategic Financial Concepts LLC - MarketBeat
How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months - Yahoo
MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq
MaxCyte signs SPL deal with TG Therapeutics - ShareCast
MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com
MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com
Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - StockTitan
MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times
Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com
MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development - Nasdaq
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell ... - The Bakersfield Californian
SG Americas Securities LLC Has $233,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Stratos Wealth Advisors LLC Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
TGTX March 28th Options Begin Trading - Nasdaq
Symphony Financial Ltd. Co. Acquires New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Precision Wealth Strategies LLC Makes New $530,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Sell" at StockNews.com - MarketBeat
Nisa Investment Advisors LLC Buys 2,803 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Trading (TGTX) With Integrated Risk Controls - Stock Traders Daily
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy - MSN
TG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8%Here's What Happened - MarketBeat
Why TGTX Stock Is Rallying Today - MSN
TG Therapeutics: Entering 2025 With Increased Investor Expectations (NASDAQ:TGTX) - Seeking Alpha
Cantor Fitzgerald Weighs in on TG Therapeutics FY2025 Earnings - Defense World
Assenagon Asset Management S.A. Decreases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha
12 Hot Stocks to Buy According to Analysts - Insider Monkey
Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN
(TGTX) Trading Signals - Stock Traders Daily
Brookstone Capital Management Acquires 624 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
FY2024 EPS Forecast for TG Therapeutics Increased by Analyst - Defense World
Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN
TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics Provides Preliminary Fourth Quarter and Full-Year Financial Results in SEC Filing - Defense World
TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):